Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Free Cash Flow (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Free Cash Flow for 11 consecutive years, with -$33.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 22.77% year-over-year to -$33.8 million, compared with a TTM value of -$188.2 million through Dec 2025, down 23.85%, and an annual FY2025 reading of -$188.2 million, down 23.85% over the prior year.
  • Free Cash Flow was -$33.8 million for Q4 2025 at Wave Life Sciences, up from -$44.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $85.0 million in Q1 2023 and bottomed at -$63.2 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$29.0 million, with a median of -$33.8 million recorded in 2024.
  • The sharpest move saw Free Cash Flow plummeted 377.36% in 2022, then soared 312.15% in 2023.
  • Year by year, Free Cash Flow stood at -$7.0 million in 2021, then tumbled by 377.36% to -$33.6 million in 2022, then grew by 0.15% to -$33.6 million in 2023, then crashed by 30.18% to -$43.7 million in 2024, then increased by 22.77% to -$33.8 million in 2025.
  • Business Quant data shows Free Cash Flow for WVE at -$33.8 million in Q4 2025, -$44.9 million in Q3 2025, and -$46.3 million in Q2 2025.